Gastro-enteropancreatic Neuroendocrine Tumor
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
CamurusCAM2029
IpsenSatoreotide trizoxetan 5-20μg
Clinical Trials (2)
Total enrollment: 29 patients across 2 trials
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Start: Oct 2021Est. completion: Jul 2028
Phase 3Active Not Recruiting
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
Start: Sep 2017Est. completion: Aug 201929 patients
Phase 2Completed
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
6m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
6m ago
Office Administrator
SystImmune
6m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
17m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
20m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
20m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
Peptide is the dominant modality (100% of programs)
2 companies competing in this space